Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- 5TH DIA Workshop
November 3, 2008
- Ono Obtains License to SC MNTX in Japan from Progenics
November 3, 2008
- Kitasato Univ. Supports PIII Trial for Uterocervical Cancer in Asia
November 3, 2008
- Policies for Development of Biosimilars Drafted by Korosho
November 3, 2008
- Daiichi Sankyo Acquires 52.5% of Ranbaxy Shares
November 3, 2008
- SURVEY／Number of Bioventures Is Declining: JBA Survey
November 3, 2008
- Smaller Firms Should Also Be Able to Benefit from FPMAJ-Proposed NHI Pricing System: Mr Nagano
November 3, 2008
- JGA to Work to Make More Data Available for Promoting Generics
November 3, 2008
- Ryukaikon to Meet on Nov. 5 for the First Time One Year after Issuing Emergency Calls
November 3, 2008
- Criteria for Premium for Dispensing Generics Must Be Discussed by Chuikyo Members
November 3, 2008
- BUSINESS NEWS IN BRIEF
November 3, 2008
- Calls by MRs Most Important Factor when Pharmacies Choose Generics
November 3, 2008
- All of the Top Seven Products ARBs in August: Rep Track Survey
November 3, 2008
- Japan, India Fail to Finalize EPA
November 3, 2008
- Stop Press／Kowa Applies for Pitavastatin in US
November 3, 2008
- OPINION／Passion and Principles: Keys to Unlocking Talent
November 3, 2008
- ASKA Obtains Approval for Menoaid Combipatch
November 3, 2008
- Korosho to Review Opinions Received on Online Sale of OTC Drugs
November 3, 2008
- Daiichi Sankyo Responds to Speculation on Status of Prasugrel NDA
November 3, 2008
- Olympus Launches Endo Capsule
November 3, 2008
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…